May 25, 2022 / 01:15PM GMT
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research Associate
Hi, and welcome to our next presentation. I'm John Sourbeer, UBS' Life Sciences and Pharma Services analyst. For our next presentation, we have NanoString; and Brad Gray, CEO and President.
R. Bradley Gray - NanoString Technologies, Inc. - CEO, President & Director
Great to be here, John.
John Newton Sourbeer - UBS Investment Bank, Research Division - Equity Research Associate
So I think we're going to start off a formal presentation and then jump into some Q&A.
R. Bradley Gray - NanoString Technologies, Inc. - CEO, President & Director
Great. So thanks, everybody, for coming out to hear a little bit about NanoString today. For the next 15 minutes or so, I want to just provide a quick company overview before we get into our Q&A. I will be making some forward-looking statements, and I'd refer you to our SEC filings for our risk factors.
So NanoString's mission
NanoString Technologies Inc at UBS Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot